GB201122047D0 - Transgenic animals - Google Patents

Transgenic animals

Info

Publication number
GB201122047D0
GB201122047D0 GBGB1122047.2A GB201122047A GB201122047D0 GB 201122047 D0 GB201122047 D0 GB 201122047D0 GB 201122047 A GB201122047 A GB 201122047A GB 201122047 D0 GB201122047 D0 GB 201122047D0
Authority
GB
United Kingdom
Prior art keywords
transgenic animals
inactivated
mice
inter alia
variable regions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1122047.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kymab Ltd
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45572821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB201122047(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kymab Ltd filed Critical Kymab Ltd
Priority to GBGB1122047.2A priority Critical patent/GB201122047D0/en
Publication of GB201122047D0 publication Critical patent/GB201122047D0/en
Priority to EP23201805.1A priority patent/EP4282879A3/en
Priority to PCT/GB2012/052956 priority patent/WO2013079953A1/en
Priority to EP15188522.5A priority patent/EP2989894B9/en
Priority to CN201280059193.7A priority patent/CN104160031B/zh
Priority to CA2857569A priority patent/CA2857569A1/en
Priority to EP17196214.5A priority patent/EP3298889A1/en
Priority to DE202012013369.1U priority patent/DE202012013369U1/de
Priority to AU2012343587A priority patent/AU2012343587B2/en
Priority to BR112014013121A priority patent/BR112014013121A2/pt
Priority to JP2014543973A priority patent/JP2015502149A/ja
Priority to HK13112514.7A priority patent/HK1185100B/en
Priority to EP12795606.8A priority patent/EP2649184B1/en
Priority to ES15188522T priority patent/ES2816899T3/es
Priority to DK12795606.8T priority patent/DK2649184T3/en
Priority to US13/843,528 priority patent/US20130243759A1/en
Priority to US15/199,575 priority patent/US20160353719A1/en
Priority to AU2016101604A priority patent/AU2016101604B4/en
Priority to AU2016244295A priority patent/AU2016244295A1/en
Priority to JP2017235119A priority patent/JP2018038428A/ja
Priority to US15/955,216 priority patent/US20180295821A1/en
Priority to AU2018217308A priority patent/AU2018217308A1/en
Priority to US16/725,707 priority patent/US20200205384A1/en
Priority to JP2020092295A priority patent/JP2020124228A/ja
Priority to AU2021203905A priority patent/AU2021203905A1/en
Priority to JP2022128160A priority patent/JP2022159413A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24046—Adamalysin (3.4.24.46)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB1122047.2A 2011-12-02 2011-12-21 Transgenic animals Ceased GB201122047D0 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
GBGB1122047.2A GB201122047D0 (en) 2011-12-21 2011-12-21 Transgenic animals
ES15188522T ES2816899T3 (es) 2011-12-02 2012-11-30 Uso de ratones o ratas transgénicos fértiles para la producción de anticuerpos que llevan regiones variables humanas
AU2012343587A AU2012343587B2 (en) 2011-12-02 2012-11-30 Fertile transgenic animals useful for producing antibodies bearing human variable regions
HK13112514.7A HK1185100B (en) 2011-12-02 2012-11-30 Use of fertile transgenic animals for producing antibodies bearing human variable regions
DK12795606.8T DK2649184T3 (en) 2011-12-02 2012-11-30 USE OF FERTILIZED TRANSGENE ANIMALS FOR THE MANUFACTURE OF ANTIBODIES CARRYING HUMAN VARIABLE REGIONS
EP15188522.5A EP2989894B9 (en) 2011-12-02 2012-11-30 Use of fertile transgenic mice or rats for producing antibodies bearing human variable regions
CN201280059193.7A CN104160031B (zh) 2011-12-02 2012-11-30 用于生产具有人可变区的抗体的可育的转基因动物
CA2857569A CA2857569A1 (en) 2011-12-02 2012-11-30 Transgenic animals
EP17196214.5A EP3298889A1 (en) 2011-12-02 2012-11-30 Use of fertile transgenic animals for producing antibodies bearing human variable regions
DE202012013369.1U DE202012013369U1 (de) 2011-12-02 2012-11-30 Fertile transgene Tiere, brauchbar zum Herstellen von Antikörpern, die humane variable Regionen tragen
PCT/GB2012/052956 WO2013079953A1 (en) 2011-12-02 2012-11-30 Fertile transgenic animals useful for producing antibodies bearing human variable regions
BR112014013121A BR112014013121A2 (pt) 2011-12-02 2012-11-30 animais transgênicos férteis úteis para produção de antibióticos portando regiões variáveis humanas
JP2014543973A JP2015502149A (ja) 2011-12-02 2012-11-30 ヒト可変領域を保有している抗体を産生するために有用な繁殖可能遺伝子導入動物
EP23201805.1A EP4282879A3 (en) 2011-12-02 2012-11-30 Use of fertile transgenic animals for producing antibodies bearing human variable regions
EP12795606.8A EP2649184B1 (en) 2011-12-02 2012-11-30 Use of fertile transgenic animals for producing antibodies bearing human variable regions
US13/843,528 US20130243759A1 (en) 2011-12-21 2013-03-15 Transgenic Animals
US15/199,575 US20160353719A1 (en) 2011-12-21 2016-06-30 Transgenic Animals
AU2016101604A AU2016101604B4 (en) 2011-12-02 2016-09-12 Fertile transgenic animals useful for producing antibodies bearing human variable regions
AU2016244295A AU2016244295A1 (en) 2011-12-02 2016-10-13 Fertile transgenic animals useful for producing antibodies bearing human variable regions
JP2017235119A JP2018038428A (ja) 2011-12-02 2017-12-07 ヒト可変領域を保有している抗体を産生するために有用な繁殖可能遺伝子導入動物
US15/955,216 US20180295821A1 (en) 2011-12-02 2018-04-17 Transgenic Animals
AU2018217308A AU2018217308A1 (en) 2011-12-02 2018-08-17 Fertile transgenic animals useful for producing antibodies bearing human variable regions
US16/725,707 US20200205384A1 (en) 2011-12-02 2019-12-23 Transgenic Animals
JP2020092295A JP2020124228A (ja) 2011-12-02 2020-05-27 ヒト可変領域を保有している抗体を産生するために有用な繁殖可能遺伝子導入動物
AU2021203905A AU2021203905A1 (en) 2011-12-02 2021-06-11 Fertile transgenic animals useful for producing antibodies bearing human variable regions
JP2022128160A JP2022159413A (ja) 2011-12-02 2022-08-10 ヒト可変領域を保有している抗体を産生するために有用な繁殖可能遺伝子導入動物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1122047.2A GB201122047D0 (en) 2011-12-21 2011-12-21 Transgenic animals

Publications (1)

Publication Number Publication Date
GB201122047D0 true GB201122047D0 (en) 2012-02-01

Family

ID=45572821

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1122047.2A Ceased GB201122047D0 (en) 2011-12-02 2011-12-21 Transgenic animals

Country Status (11)

Country Link
US (2) US20130243759A1 (https=)
EP (4) EP2649184B1 (https=)
JP (4) JP2015502149A (https=)
CN (1) CN104160031B (https=)
AU (5) AU2012343587B2 (https=)
BR (1) BR112014013121A2 (https=)
CA (1) CA2857569A1 (https=)
DE (1) DE202012013369U1 (https=)
ES (1) ES2816899T3 (https=)
GB (1) GB201122047D0 (https=)
WO (1) WO2013079953A1 (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5827127B2 (ja) * 2008-12-18 2015-12-02 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム ヒト化抗体を発現する非ヒトトランスジェニック動物及びその使用
DK3622815T3 (da) 2009-07-08 2023-06-26 Kymab Ltd Gnavermodeller og terapeutiske molekyler
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
SMT201700023T1 (it) 2010-08-02 2017-03-08 Regeneron Pharma Topi che producono proteine leganti vl
ME02106B (me) 2011-02-25 2015-10-20 Regeneron Pharma Miševi sa adam6
HUE047278T2 (hu) 2011-08-05 2020-04-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
BR112014006394A2 (pt) 2011-09-19 2017-03-28 Kymab Ltd manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
SG11201401181YA (en) 2011-10-17 2014-04-28 Regeneron Pharma Restricted immunoglobulin heavy chain mice
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SG10201605675WA (en) 2011-12-20 2016-09-29 Regeneron Pharma Humanized light chain mice
WO2013138681A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
EP2825036B1 (en) 2012-03-16 2018-05-02 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
EP3539374A1 (en) 2012-03-16 2019-09-18 Regeneron Pharmaceuticals, Inc. Non-human animals expressing ph-sensitive immunoglobulin sequences
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
ME03551B (me) 2012-06-12 2020-07-20 Regeneron Pharma Humanizovane nehumane živoтinje sa ograničenim lokusima imunoglobulinskog тeškog lanca
MY178882A (en) 2013-02-20 2020-10-21 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences
EP4545567A3 (en) * 2013-03-13 2025-08-13 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
EP3988649B1 (en) * 2013-09-18 2024-11-27 Kymab Limited Methods, cells and organisms
GB201316644D0 (en) 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
AU2014330922A1 (en) 2013-10-01 2016-03-03 Kymab Limited Animal models and therapeutic molecules
WO2015108102A1 (ja) 2014-01-15 2015-07-23 国立大学法人 群馬大学 Ａｔｐ可視化動物およびその用途
CA3124228C (en) 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
AU2015231025A1 (en) 2014-03-21 2016-09-15 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
PL3560954T3 (pl) 2014-04-03 2021-12-13 Igm Biosciences, Inc. Zmodyfikowany łańcuch J
SI3161128T1 (sl) * 2014-06-26 2019-02-28 Regeneron Pharmaceuticals, Inc. Postopki in sestavki za ciljano genetsko spremembo in postopki uporabe
EP3957738A1 (en) 2015-03-04 2022-02-23 IGM Biosciences, Inc. Cd20 binding molecules and uses thereof
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
EP3355913B1 (en) 2015-09-30 2024-10-30 IGM Biosciences, Inc. Binding molecules with modified j-chain
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
JP2019513415A (ja) * 2016-04-04 2019-05-30 イーティーエッチ チューリッヒ タンパク質産生及びライブラリー生成のための哺乳類細胞株
CA3079681A1 (en) * 2017-10-20 2019-04-25 Fred Hutchinson Cancer Research Center Systems and methods to produce b cells genetically modified to express selected antibodies
PT3773713T (pt) 2018-04-06 2025-07-29 Regeneron Pharma Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia
CA3125380A1 (en) 2019-02-18 2020-08-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
EP3785536B2 (en) * 2019-08-28 2025-09-17 Trianni, Inc. Adam6 knockin mice
JP2023529846A (ja) 2020-06-02 2023-07-12 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド 共通軽鎖免疫グロブリン遺伝子座を有する遺伝子改変非ヒト動物
US20220090060A1 (en) 2020-09-11 2022-03-24 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
CN116848254B (zh) 2020-12-16 2026-03-17 瑞泽恩制药公司 表达人源化Fcα受体的小鼠
CN118325896A (zh) * 2023-01-09 2024-07-12 上海交通大学医学院 一种抗体无功能等位基因小鼠模型及其构建方法和应用
TW202600011A (zh) 2023-01-18 2026-01-01 美商基利科學股份有限公司 具有經改變重鏈基因座之嵌合基因轉殖免疫球蛋白小鼠及其製造及使用方法
WO2025055311A1 (zh) * 2023-09-15 2025-03-20 赛业（苏州）生物科技有限公司 用于制备抗体的基因修饰小鼠及其制备方法
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
WO2026035843A2 (en) 2024-08-06 2026-02-12 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3320448C2 (de) 1983-06-07 1986-09-04 Elasto-Press Schmitz GmbH, 3250 Hameln Mangelband für Wäschemangeln
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
BE1007904A3 (nl) 1993-12-23 1995-11-14 Dsm Nv Werkwijze voor de bereiding van een alkanol en/of een alkanon.
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
AU3507297A (en) 1996-06-26 1998-01-14 Baylor College Of Medicine Chromosomal rearrangement by insertion of two recombination substrates
US6355412B1 (en) 1999-07-09 2002-03-12 The European Molecular Biology Laboratory Methods and compositions for directed cloning and subcloning using homologous recombination
JP2003523899A (ja) * 2000-02-24 2003-08-12 参天製薬株式会社 製品ラベルからの汚染を防ぐための容器
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
DE60239420D1 (de) * 2001-12-21 2011-04-21 Thrombogenics Nv Zusammensetzungen für die in vitro herleitung und kultur embryonaler stammzellinien mit keimbahnübertragungsfähigkeit und für die kultur adulter stammzellen
WO2004041863A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
US8048999B2 (en) 2005-12-13 2011-11-01 Kyoto University Nuclear reprogramming factor
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
JP5813321B2 (ja) 2007-03-23 2015-11-17 ウィスコンシン アラムニ リサーチ ファンデーション 体細胞の再プログラム化
CN105861443A (zh) 2007-04-07 2016-08-17 怀特黑德生物医学研究所 体细胞重编程
EP2164951A2 (en) 2007-05-30 2010-03-24 The General Hospital Corporation Methods of generating pluripotent cells from somatic cells
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
KR20100103810A (ko) * 2007-12-10 2010-09-28 알리바 바이오파마수티컬스, 아이엔씨. 동종 재조합에 의한 표적화된 영역의 순차적인 치환 방법
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
DK3622815T3 (da) 2009-07-08 2023-06-26 Kymab Ltd Gnavermodeller og terapeutiske molekyler
GB0915523D0 (en) 2009-09-07 2009-10-07 Genome Res Ltd Cells and methods for obtaining them
EP4502152A3 (en) 2009-10-06 2025-04-30 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
ME02106B (me) * 2011-02-25 2015-10-20 Regeneron Pharma Miševi sa adam6
HUE047278T2 (hu) * 2011-08-05 2020-04-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
SG10201605675WA (en) * 2011-12-20 2016-09-29 Regeneron Pharma Humanized light chain mice
EP3597038B1 (en) * 2012-02-01 2021-04-21 Regeneron Pharmaceuticals, Inc. Humanized rodents that express heavy chains containing vl domains

Also Published As

Publication number Publication date
JP2015502149A (ja) 2015-01-22
JP2018038428A (ja) 2018-03-15
AU2012343587A1 (en) 2014-05-15
EP4282879A2 (en) 2023-11-29
AU2012343587B2 (en) 2016-07-14
EP4282879A3 (en) 2024-03-20
HK1185100A1 (zh) 2014-02-07
US20130243759A1 (en) 2013-09-19
JP2022159413A (ja) 2022-10-17
AU2021203905A1 (en) 2021-07-08
JP2020124228A (ja) 2020-08-20
WO2013079953A1 (en) 2013-06-06
EP2989894A1 (en) 2016-03-02
ES2816899T3 (es) 2021-04-06
CN104160031A (zh) 2014-11-19
US20160353719A1 (en) 2016-12-08
AU2018217308A1 (en) 2018-09-06
AU2016101604A4 (en) 2016-10-06
EP3298889A1 (en) 2018-03-28
CA2857569A1 (en) 2013-06-06
DE202012013369U1 (de) 2016-08-23
AU2016101604B4 (en) 2016-11-24
EP2649184B1 (en) 2015-10-07
CN104160031B (zh) 2017-03-08
BR112014013121A2 (pt) 2019-09-24
EP2649184A1 (en) 2013-10-16
EP2989894B9 (en) 2022-12-14
AU2016244295A1 (en) 2016-11-03
EP2989894B1 (en) 2020-08-12

Similar Documents

Publication Publication Date Title
GB201122047D0 (en) Transgenic animals
IL282452B (en) Histidine-engineered light chain antibodies, and non-human animals genetically modified for their preparation
IN2014MN01879A (https=)
IL264358A (en) Histidine engineered light chain antibodies and non-human animals genetically engineered to produce them
EA201592269A1 (ru) Способы и композиции для снижения иммуносупрессии опухолевыми клетками
EA201790664A1 (ru) Антитела против мезотелина и иммуноконъюгаты
SMT201300046B (it) Modelli animali e molecole terapeutiche
CY1122978T1 (el) Αντισωματα εναντι-vla-4
WO2014093908A3 (en) Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
MX2014012978A (es) Regiones de anticuerpo modificado y sus usos.
CR20140585A (es) Proteinas de union a antigeno st2
MX369740B (es) Anticuerpos contra claudina 18.2 útiles en el diagnóstico de cáncer.
TR201810255T4 (tr) Modifiye edilmiş immunoglobulin ağır zincir sekanslarına sahip olan insan olmayan hayvanlar.
MX2015004421A (es) Conjugados del anticuerpo pirrolobenzodiazepina.
PL3702368T3 (pl) Przeciwciała o zmodyfikowanym powinowactwie do FcRn, które wspomagają klierens antygenu
MY178142A (en) Anti-phf-tau antibodies and their uses
EA201391298A1 (ru) Неводные концентрированные суспензионные композиции с пониженной вязкостью на основе антител
CL2014000574A1 (es) Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano.
UY34411A (es) Inmunoenlazantes dirigidos contra esclerostina
MA32712B1 (fr) Anticorps anti-vegf/anti-ang-2 bispecifique
WO2015049517A3 (en) Animal models and therapeutic molecules
NZ703973A (en) Complex chromosome engineering for production of human antibodies in transgenic animals
PH12013500933A1 (en) Methods and compositions for neural disease immunotherapy
EA201390660A1 (ru) Модифицированные никотиновые соединения и связанные способы

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)